Paper Details

  1. Home
  2. Paper Details

One-year experience with intravenous treprostinil for pulmonary arterial hypertension.

Author: BarstRobyn J, BenzaRaymond L, Gomberg-MaitlandMardi, McLaughlinVallerie V, PomsAbigail, TapsonVictor F

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Continuous intravenous treprostinil, a prostacyclin analog, holds potential advantages over intravenous epoprostenol for treating advanced pulmonary arterial hypertension (PAH). However, long-term efficacy and safety data for intravenous treprostinil in PAH are limited.
Paper Details　
Original Abstract of the Article :
Intravenous (IV) epoprostenol has been the mainstay of therapy in advanced pulmonary arterial hypertension (PAH). Continuous IV treprostinil has several potential advantages over IV epoprostenol; however, there has been a lack of published long-term efficacy and safety data on IV treprostinil in PAH...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.healun.2013.06.008

データ提供：米国国立医学図書館（NLM）

Intravenous Treprostinil: A New Path for Pulmonary Arterial Hypertension

The [Treatment] of [Pulmonary arterial hypertension (PAH)] is an ongoing quest for [Effective and durable therapies]. This study investigates the [Efficacy and safety] of [Intravenous treprostinil] in patients with [PAH], comparing it to the [Current standard of care] with [Intravenous epoprostenol]. It’s like exploring a new trail through the desert, seeking a more efficient and sustainable way to manage this complex condition. The researchers found that [Intravenous treprostinil] showed [Promising results] in terms of [Improving hemodynamics and reducing symptoms], suggesting that it may offer a viable alternative to [Intravenous epoprostenol].

A New Trail in the Desert: Intravenous Treprostinil Shows Promise for PAH

The study provides encouraging evidence for the [Efficacy] of [Intravenous treprostinil] in [PAH], offering a potential [New treatment option] for patients struggling with this challenging condition. It’s like discovering a new source of water in the desert, providing a vital resource for those facing a challenging journey. The findings suggest that [Intravenous treprostinil] may offer a [Safer and more convenient] alternative to [Intravenous epoprostenol], improving the [Quality of life] for patients with [PAH].

Navigating the Desert of PAH Treatment: Seeking Effective and Sustainable Solutions

This study emphasizes the importance of [Continuing research and development] in the [Treatment] of [PAH]. It’s like surveying the desert landscape, identifying new resources and pathways, and striving for a better future for patients facing this challenging condition. The findings suggest that [Intravenous treprostinil] may represent a significant advancement in [PAH treatment], offering a potential for [Improved outcomes] and [Increased quality of life] for patients.

Dr.Camel's Conclusion

This study offers encouraging evidence for the efficacy and safety of intravenous treprostinil in treating pulmonary arterial hypertension. The findings suggest that intravenous treprostinil may offer a viable alternative to intravenous epoprostenol, potentially improving outcomes and quality of life for patients with PAH.

Date :
  1. Date Completed 2014-04-03
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

23953817

DOI: Digital Object Identifier

10.1016/j.healun.2013.06.008

Related Literature

Article Analysis
・Side Effects of epoprostenol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.